硼替佐米联合地塞米松治疗多发性骨髓瘤的临床分析(1)
[摘要] 目的 探討硼替佐米联合地塞米松治疗多发性骨髓瘤的应用效果。方法 方便选取2017年5月—2018年5月期间该院收治的60例多发性骨髓瘤患者为研究对象，根据治疗方案不同分两组，对照组用常规治疗，观察组用硼替佐米联合地塞米松治疗，对比两种方案实施情况。 结果 观察组治疗后的IL-6、IL-17、TGF-β数值为(92.02±5.24)pg/mL、(120.24±10.28)pg/mL、(1.82±0.34)pg/mL，对照组数值为(108.53±11.24)pg/mL、(152.36±15.26)pg/mL、(1.96±0.42)pg/mL，观察组数值低于对照组数值，差异有统计学意义(t=5.653 5、5.452 8、5.486 8，P<0.05);观察组治疗后的CD3+CD4+、CD3+CD8+、CD3+CD4+/CD3+CD8+为(43.89±2.54)、(22.26±2.58)、(1.86±0.24)，对照组为(37.17±2.86)、(30.24±3.75)、(1.22±0.16);观察组CD3+CD8+数值低于对照组数值，CD3+CD4+、CD3+CD4+/CD3+CD8+高于对照组数值，差异有统计学意义(t=5.654 5、5.378 5、5.983 5，P<0.05)。 结论 硼替佐米联合地塞米松治疗多发性骨髓瘤的应用效果非常显著，各项症状和治疗得到有效改善，值得应用。
, 百拇医药
[关键词] 硼替佐米;地塞米松;多发性骨髓瘤;临床分析
[中图分类号] R733.3 [文献标识码] A [文章编号] 1674-0742(2019)07(b)-0092-03
Clinical Analysis of Bortezomib Combined with Dexamethasone in the Treatment of Multiple Myeloma
FU Mei-hua
Department of Hematology， Qinzhou First People's Hospital， Qinzhou， Guangxi， 535009 China
[Abstract] Objective To investigate the effect of bortezomib combined with dexamethasone in the treatment of multiple myeloma. Methods Sixty patients with multiple myeloma admitted to our hospital from May 2017 to May 2018 were convenient enrolled in the study. They were divided into two groups according to the treatment plan. The control group was treated with conventional therapy， and the observation group was treated with bortezomib combined with dexamethasone treatment; compared the implementation of the two programs. Results The IL-6， IL-17 and TGF-β values in the observation group were (92.02±5.24)pg/mL， (120.24±10.28) pg/mL， (1.82±0.34) pg/mL， and the control group of (108.53±11.24)pg/mL， (152.36±15.26) pg/mL， (1.96±0.42) pg/mL， the observation group value was lower than the control group， and the statistics were significant (t=5.653 5， 5.452 8， 5.486 8， P<0.05); CD3+CD4+， CD3+CD8+， CD3+CD4+/CD3+CD8+ in the observation group were (43.89±2.54)， (22.26±2.58)， (1.86±0.24)， and the control group was (37.17±2.86)， (30.24±3.75)， (1.22±0.16); the CD3+CD8+ value of the observation group was lower than that of the control group， and the CD3+CD4+， CD3+CD4+/CD3+CD8+ values were higher than the control group， and the statistics were significant. (t=5.654 5， 5.378 5， 5.983 5， P<0.05). Conclusion The application effect of bortezomib combined with dexamethasone in the treatment of multiple myeloma is very significant， and the symptoms and treatments are effectively improved， which is worthy of application., 百拇医药(符美华)
, 百拇医药
[关键词] 硼替佐米;地塞米松;多发性骨髓瘤;临床分析
[中图分类号] R733.3 [文献标识码] A [文章编号] 1674-0742(2019)07(b)-0092-03
Clinical Analysis of Bortezomib Combined with Dexamethasone in the Treatment of Multiple Myeloma
FU Mei-hua
Department of Hematology， Qinzhou First People's Hospital， Qinzhou， Guangxi， 535009 China
[Abstract] Objective To investigate the effect of bortezomib combined with dexamethasone in the treatment of multiple myeloma. Methods Sixty patients with multiple myeloma admitted to our hospital from May 2017 to May 2018 were convenient enrolled in the study. They were divided into two groups according to the treatment plan. The control group was treated with conventional therapy， and the observation group was treated with bortezomib combined with dexamethasone treatment; compared the implementation of the two programs. Results The IL-6， IL-17 and TGF-β values in the observation group were (92.02±5.24)pg/mL， (120.24±10.28) pg/mL， (1.82±0.34) pg/mL， and the control group of (108.53±11.24)pg/mL， (152.36±15.26) pg/mL， (1.96±0.42) pg/mL， the observation group value was lower than the control group， and the statistics were significant (t=5.653 5， 5.452 8， 5.486 8， P<0.05); CD3+CD4+， CD3+CD8+， CD3+CD4+/CD3+CD8+ in the observation group were (43.89±2.54)， (22.26±2.58)， (1.86±0.24)， and the control group was (37.17±2.86)， (30.24±3.75)， (1.22±0.16); the CD3+CD8+ value of the observation group was lower than that of the control group， and the CD3+CD4+， CD3+CD4+/CD3+CD8+ values were higher than the control group， and the statistics were significant. (t=5.654 5， 5.378 5， 5.983 5， P<0.05). Conclusion The application effect of bortezomib combined with dexamethasone in the treatment of multiple myeloma is very significant， and the symptoms and treatments are effectively improved， which is worthy of application., 百拇医药(符美华)